Brightline-3: A Phase III, Randomized, Open-label, Multi-center Trial of Brigimadlin + Ezabenlimab Compared to Gemcitabine + Docetaxel for Second-line Treatment of Patients With Advanced TP53 Wild-type Soft Tissue Sarcoma Subtypes
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Brigimadlin (Primary) ; Ezabenlimab (Primary) ; Docetaxel; Gemcitabine
- Indications Malignant fibrous histiocytoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms Brightline-3
- Sponsors Boehringer Ingelheim
Most Recent Events
- 17 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 May 2024 Planned initiation date changed from 4 Jun 2024 to 27 Jun 2024.
- 22 Apr 2024 New trial record